Measures in the first year of therapy predict the response to interferon β in MS (Q57601917)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Measures in the first year of therapy predict the response to interferon beta in MS (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Mar Tintoré

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Jaume Sastre Garriga

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Alejandro Horga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Xavier Montalban

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

J Castilló

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

A Rovira

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

C Nos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

M Comabella

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

X Aymerich

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

848-853

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Transcription-based prediction of response to IFNbeta using supervised computational methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

A solution to the problem of separation in logistic regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Disability as an outcome in MS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509104591

21 January 2018

Identifiers

DOI

10.1177/1352458509104591

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19542263%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference